NCT02580773 - Therapeutic Anticoagulation Strategy for Acute Chest Syndrome | Biotech Hunter

Enrollment

198

Participants

Timeline

Start Date

December 16, 2016

Primary Completion Date

February 4, 2021

Study Completion Date

September 15, 2021

Conditions

AnemiaSickle CellAcute Chest SyndromeLow-Molecular-Weight Heparin

Interventions

DRUG

Prophylactic anticoagulation ( INNOHEP®)

subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)

DRUG

Curative anticoagulation ( INNOHEP®)

subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)

Trial Locations (1)

Henri Mondor Hospital, Créteil